Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

MedGenome Names Dr. Amit Kakar as New Chairman of the Board

NextEdge Admin

11 Sep 2024

2 min 57 sec

MedGenome, a global leader in genomics-driven diagnostics and research services, has appointed Dr. Amit Kakar as Chairman of its Board, succeeding Dr. Felix Olale. Dr. Kakar, who has served on the MedGenome board since 2022, is Managing Partner and Head of Asia at Novo Holdings, a prominent life sciences investor. With over 30 years of experience in the healthcare and life sciences industries, Dr. Kakar has held senior positions at Avenue Capital, GE Healthcare, and Everlife Asia, and currently serves on the boards of Doctor Anywhere, ESCO, and Qure.ai.

Dr. Kakar brings a wealth of expertise in healthcare investments and operations, having been involved in healthcare leadership across Asia, the US, and Europe. In his new role, he will guide MedGenome’s growth strategy, emphasizing expanding its global footprint and making healthcare solutions affordable and accessible. MedGenome’s mission is to transform healthcare through its innovative genomic research and diagnostics, providing critical insights at the molecular level to diagnose complex diseases and enable advancements in precision medicine.

MedGenome is a leader in genetic testing in India, offering more than 1,300 tests across key areas such as oncology, reproductive health, inherited diseases, infectious diseases, and preventive wellness. The company has sequenced over 350,000 genomes and exomes, built a network of over 5,000 hospitals and 15,000 clinicians across India, and created the largest database of South Asian genetic variants. Its consumer-focused division, Genessense, offers preventive wellness tests aimed at understanding genetic predispositions to lifestyle diseases.

MedGenome operates globally, with the largest CAP-accredited genetic testing lab in South Asia, a high-throughput Next-Generation Sequencing lab in California, and presence in the US, India, Singapore, and Africa. Mahesh Pratapneni, MedGenome’s Group CEO and Co-founder, commended Dr. Kakar’s leadership and sector expertise, expressing confidence in his ability to lead MedGenome’s next phase of growth.